Barbara Drevlow, MD:

1.      Verbalize which medications contribute to bone loss and fracture risk

2.      Define the mechanisms of bone loss and treatment strategies

3.      Articulate the 2017 Guidelines for treatment and prevention of Glucocorticoid induced osteoporosis

Amanda Myers, MD:

1.      Define the mechanism of action of romosozumab

2.      Describe the main romosozumab trials and be able to quantify the reduction of fracture risk

3.      Articulate the risks and benefits of romosozumab therapy, specifically the cardiovascular risks

Stacy Weinberg, MD:

1.    Articulate the pathogenesis of adverse events including atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ)

2.    Define the frequency and risk factors for development of ONJ in patients on medications to treat osteoporosis

3.    Describe the frequency and risk factors for development of AFF in patients on medications to treat osteoporosis